144 results about "A baumannii" patented technology

The invention discloses acinetobacter baumannii, and a screening method and an application thereof in degradation of an azo dye Congo red. The stain is named as acinetobacter baumannii YNWH226, is preserved in China general microbiological culture collection center, and has the preservation number of CGMCC No.7922. The invention provides the new acinetobacter baumannii and the application thereof in degradation of the dye. Especially, the acinetobacter baumannii can effectively degrade the azo dye Congo red, has quite good decoloration and mineralization effects on Congo red wastewater, can completely mineralize the Congo red under a simple aerobic condition, and has great significance on governance of dye pollution and study on aerobic degradation of the azo dye.

The invention provides a pathogen inspection reagent, and concretely discloses a primer probe combination and a kit for combined inspection of 15 kinds of respiratory tract infection pathogens. By aiming at specific target sequences of the gene sequence conserved region of klebsiella pneumoniae, haemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, escherichia coli, chlamydia pneumoniae, mycobacterium tuberculosis, stenotrophomonas maltophilia, baumanii, mycoplasma pneumoniae, enterococcus faecalis, ligionella pneumohpillia, streptococcus pneumoniae, bacillus pyocyaneus and mycobacterium abscessus, primers and probes which do not have mutual crossed reaction are designed, so that the problem that detection probes of different pathogens can easily generate mutual influenceor interference is solved; the combination and matching of different primers and probes are ensured; the goal of simultaneously performing efficient specific inspection at the same temperature can also be achieved.

The invention relates to the technical field of medical detection, and in particular, relates to a primer and probe combination and a kit for detecting human pathogenic bacteria. The kit comprises theprimer and probe combination for detecting pseudomonas aeruginosa, escherichia coli, klebsiella pneumoniae, staphylococcus epidermidis, staphylococcus aureus, enterococcus faecium, human staphylococcus and acinetobacter baumannii. According to the kit, the primer and probe combination is adopted, multiple digital PCR is combined, the pathogenic bacteria types and the target nucleic acid copy number in the detection range can be rapidly and accurately identified, the detection method has high sensitivity, and positive detection of low-copy nucleic acid fragments of pathogenic bacteria is guaranteed; meanwhile, the variety of the pathogenic bacteria or the change of the copy number of the target nucleic acid fragment in the body of a pathogenic bacteria infected patient can be dynamically monitored, the treatment effect is assisted and evaluated in time, and reference is provided for optimization of a doctor clinical scheme.

The invention provides a preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as a preparation and a kit. The preparation method is characterized by comprising the following steps of: preparing antigen liquor, immunizing hens, and separating and purifying the IgY. In-vivo and in-vitro experiments prove that the prepared specificity IgY has specific binding activity to the acinetobacter baumannii, can be used for effectively inhibiting the growth of the acinetobacter baumannii and alleviating a toxic effect generated by the acinetobacter baumannii, can be applied to prevention, treatment and diagnostic analysis on infectious diseases and complications of the acinetobacter baumannii, and has wide application prospect.

The invention discloses Acinetobacter baumannii AL-6 and an application thereof. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) in November 8th, 2016, and the preservation number is CGMCC No. 13248. The strain can conduct denitrification through heterotrophic nitrification-aerobic denitrification. Under the aerobic condition, with CH3COONa as a carbon source and NH4+-N as a nitrogen source, removal of 81.9-99.9% of NH4+-N and 59.7-90.8% of TN can be achieved; with NO3--N as a nitrogen source, the removal rate of NO3--N is 50.2%, and the removal rate of TN is 48.2%; with NO2--N as a nitrogen source, the removal rate of NO2--N is 50.3%, and the removal rate of TN is 48.8%. The strain AL-6 has good application prospects in the field of treatment of wastewater containing highly concentrated ammonia-nitrogen or nitrate nitrogen or nitrite nitrogen.

The invention relates to an application of norwogonin to preparation of medicines for treating acinetobacter baumannii infection and complications caused by the acinetobacter baumannii infection. Acinetobacter baumannii is resistant to a variety of antibiotics and the norwogonin can inhibit growth of the acinetobacter baumannii with multidrug resistance; an in-vitro drug susceptibility test proves that during independent use of the norwogonin, the minimum inhibitory concentration of the norwogonin is half of the minimum inhibitory concentration of the conventional therapeutic medicine imipenem, which means that the inhibitory effect of the norwogonin is better; combination of the norwogonin and the imipenem can achieve a synergistic effect on the growth of the acinetobacter baumannii with the multidrug resistance; and an acute toxicity test on a mouse proves that the using safety of the norwogonin is high, which means that the norwogonin has a good medicinal prospect.

The invention discloses indole compounds represented by the general formula defined in the specification and salts and preparation method thereof, corresponding medical uses of the compounds and the salts thereof, and drugs and disinfectants containing the compounds and the salts thereof. A lot of experiments prove that the compounds and the salts thereof have good bacteriostatic and bactericidal activity on MRSA (drug-resistant staphylococcus aureus), MDR K.pneumonia (drug-resistant klebsiella pneumonia), and MDR A.baumanii (drug-resistant acinetobacter baumannii). In the formula, X is methylene, carbonyl or sulfonyl; R1 is fluorine, chlorine, bromine, methoxy acyl, nitro or hydrogen; R2 is methoxyl acyl, (p-methoxyl acyl)phenyl, (p-trifluoro oxy)phenyl, (p-trifluoro)phenyl, (m-methoxy acyl)phenyl, (m-trifluoro oxy)phenyl, (p-fluoro m-chloro)phenyl or hydrogen; and HA is inorganic acid or a part of organic acid with strong acidity, preferably hydrochloric acid or hydrobromic acid.

The invention relates to a microbial compound fungicide for treating oil base drilling cuttings as well as a preparation method and application of the microbial compound fungicide. The compound fungicide comprises pseudomonas aeruginosa with a collection number of CGMCC NO:8983 and acinetobacter baumannii with the collection number of CGMCCNO:8984. The invention further discloses the preparation method of the microbial compound fungicide and application of the compound fungicide in treatment of oil base drilling cuttings. The preparation method includes preparation methods of liquid and solid fungicides.

The invention relates to a 1 A1S-1969 recombinant protein and a preparation method and application thereof. The recombinant protein comprises 46th to 414th site amino acid sequence of 1 A1S-1969, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 5. The recombinant protein is high in expression amount, easy to separate and purify, efficient and safe, can be directly used with an adjuvant, and is used for the preparation of an acinetobacter baumannii infection resistant subunit vaccine and a related detection kit. Confirmed by animal experiments, the genetic engineering recombinant subunit vaccine has good acinetobacter baumannii infection resistant immune protection effect, lays a foundation for the further study on combined vaccines and multicomponent fusion vaccines, and plays an important role for development and application of prevention and control vaccines and diagnostic kits.

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and / or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.

The invention aims to provide a multiple PCR detection kit and a method for identifying susceptible bacteria species for intracranial post-operation to eliminate endogenous nucleic acid contamination. The detected bacteria species are the following common bacteria: staphylococcus aureus, enterococcus faecalis, streptococcus pneumoniae, escherichia coli, bacillus pyocyaneus, klebsiella pneumoniae and acinetobacter baumannii. Meanwhile, the invention provides the method to eliminate the endogenous nucleic acid contamination in a raw material of a PCR system and exclude a false positive experimental result of a PCR caused by the endogenous nucleic acid contamination. The detecting method using the kit has the advantages of that the operation is simple and fast, the detection cost is lowered, the detection result is accurate, and the false positive result is reduced. A negative control and a positive control are added in the amplification step, so that the judgment of false positive and false negative is effectively improved, and the detection accuracy is higher.

The invention belongs to the field of molecular biology and immunology, and more specifically provides an acinetobacter baumannii subunit vaccine antigen protein and applications thereof. The gene nucleic acid sequence of acinetobacter baumannii outer membrane protein OmpW is represented by SEQ IDNO:1, an obtained encoded protein is the acinetobacter baumannii subunit vaccine antigen protein, and amino acid sequence of the acinetobacter baumannii subunit vaccine antigen protein is represented by SEQ IDNO:2. A preparation method comprises following steps: prokaryotic expression plasmid OmpW-pThioHisA of OmpW vaccine atigen is constructed, and is transformed into BL21(DE3); after inducible expression, recycling and purification of OmpW recombinant protein are carried out, and the OmpW recombinant protein is mixed with aluminum hydroxide adjuvant so as to obtain a mixed solution which is capable of stimulating bodies to generate specific antibodies, wherein the specific antibodies possesses high efficiency immunoprotection effects on acinetobacter baumannii infection, and can be used for preventing acinetobacter baumannii infection.

The invention discloses a molecular beacon and a kit for quickly identifying various clinically common bacteria and belongs to the technical field of microbiological detection. The sequences SEQ ID of the molecular beacon are as shown in v6p1, v6p2, v1p1 and v1r. Through comparison between various clinically common bacteria 16s ribosome RNA sequences in an NCBI gene sequence database and design of the molecular beacon at a tag sequence, clinically common 18 bacteria, including baumanii, A.hydrophila, burkholderia cepacia, citrobacter freundii, enterobacter cloacae, enterococcus faecium, enterococcus faecalis, enterobacter aerogenes, escherichia coli, klebsiella pneumoniae, listeria monocytogenes, proteus mirabilis, pseudomonas aeruginosa, staphylococcus epidermidis, staphylococcus aureus, salmonella, serratia marcescens and stenotrophomonas maltophilia, can be quickly identified. The invention further discloses the kit containing the molecular beacon and used for detecting various bacteria, and the kit can quickly and accurately identify various clinically common bacteria.

The invention relates to a method for degrading nitrobenzene in waste water, characterized by inoculating nitrobenzene low temperature-resistant bacteria in logarithmic growth phase to the waste water containing nitrobenzene according to a volume percent of 1-20%, regulating the pH value to 4-9, and culturing for 48 h under the conditions of vibration, wherein the nitrobenzene low temperature-resistant bacteria are acinetobacter baumannii, preferably acinetobacter baumannii strain cc-2. According to the invention, nitrobenzene can be effectively degraded in a low temperature environment, the defects of restraint of growth and metabolism of the strain in low temperature and insufficient capability of degrading nitrobenzene are made up, the capacity of the strain for degrading nitrobenzene in low temperature is raised, and the method provides the treatment of nitrobenzene in low temperature with a technology support.

The invention discloses Ab Ata protein immunogenicity and provides a protein which comprises Ab Ata protein N-terminal alpha-spiral part 39 amino acids and an adjuvant protein; the amino acid sequences of the Ab Ata protein N-terminal alpha-spiral part 39 amino acids are 127th-165th sites of the sequence 2 respectively. According to the Ab Ata, the N-terminal alpha-spiral part 39 amino acids are cut out, fused with CTB and expressed in BL21. Through ni-sepharose purification, peritoneal immunity is performed at 40 mu g / mice, the immunogenicity and the immune protective of the Ab Ata protein are verified through animal experiments, and the Ab Ata protein has excellent Ab infection resistance.

The invention relates to polypeptide capable of inhibiting and killing bacteria, and in particular relates to multiple medicine-resisting bacteria. The polypeptide is remarkable in effect of killing or inhibiting methicillin-resistant staphylococcus epidermidis, klebsiella pneumoniae, baumanii and / or escherichia coli. The invention further relates to a composition with the defined polypeptide, and an application of the defined polypeptide and the composition thereof in preparation of medicines and in killing or inhibiting of multiple in-vitro medicine-resisting bacteria.

The invention relates to analysis of an acinetobacter baumannii (Ab) Sv4-serotype O antigen by using an MGB probe-based real-time fluorescent TaZMan polymerase chain reaction rapid detection system. Aspecific gene, Wzy, in an acinetobacter baumannii O antigen gene cluster is adopted as a target gene so as to establish a primer and MGB probe for typing the acinetobacter baumannii O antigen, and areliable route is provided for typing of the O antigen of acinetobacter baumannii in blood, urine, pus and a respiratory tract. When the MGB probe is applied to detection of acinetobacter baumannii inthe blood, urine, pus and respiratory tract, and O-antigen typing of acinetobacter baumannii is performed, high sensitivity, high specificity, rapid detection and other advantages are achieved.

The invention discloses a vaccine for preventing and treating diseases caused by Acinetobacter baumannii and a preparation method thereof. The vaccine for preventing and treating the diseases caused by the Acinetobacter baumannii provided by the invention has an active component which is an Acinetobacter baumannii glycoprotein obtained through glycosylation of a protein composed of bases from site20 to site 156 of SEQ ID No. 1 or bases from site 1 to site 156 of SEQ ID No. 1. According to the invention, Acinetobacter baumannii glycoprotein modified rCTB4573 prepared by a genetic engineering method is used for preparation of an Acinetobacter baumannii glycoprotein protein conjugate vaccine; uniformity of the vaccine can be improved; production efficiency of the vaccine is improved; the cost is reduced; extensive application prospect is achieved; and the vaccine can be used for preventing the diseases caused by pathogenic Acinetobacter baumannii.

The present invention relates to an antibacterial synergist, a preparation method and uses thereof, and specifically discloses a compound represented by a formula (I) and having antibacterial synergyactivity, or an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof, and a preparation method thereof. The present invention further discloses a medical composition containing the compound, and uses thereof. According to the present invention, the compound can effectively enhance the antibacterial activity of polymyxin B against Acinetobacter baumannii and Klebsiella pneumoniae, and can be used for the antibacterial treatment of pathogenic bacteria insensitive to polymyxin or having low bacterial inhibition activity. The formula (I) is defined in the specification.

The invention relates to bioremediation preparation for industrial waste water produced by using the concentration isoelectric point technology to prepare sodium glutamate. The bioremediation preparation is mixed and prepared by nitrosomonas europaea, paracoccus pantotrophus, acinetobacter baumannii, aspergillus niger, rhodococcus sp., alcaligenes faecalis, streptomyces lateritius, candida albicans, paenibacillus polymyxa and an absorbent carrier. The bioremediation preparation has the advantages that the preparation contains various microorganisms with good degrading ability to degradation-resistant pollutants, various strains are reasonably combined, and the preparation is good in degrading effect and promising in application prospect.

The invention relates to application of blue light activated (S)-blebbistatin molecules to killing of drug-resistant acinetobacter baumannii, and a method for killing the drug-resistant acinetobacterbaumannii through the blue light activated (S)-blebbistatin molecules. (S)-blebbistatin molecules are used for cooperating with blue light, and the (S)-blebbistatin molecules generate strong-oxidativehydroxyl radicals (.OH) under blue light irradiation, and can kill the drug-resistant acinetobacter baumannii. (S)-blebbistatin and a bacterial solution are mixed evenly to be irradiated under the blue light and then smeared or dotted on the surface of a flat plate for a period of time, and then it can be observed that the clinical drug-resistant acinetobacter baumannii is killed. The sterilizingefficiency is improved with increasing of the time, and the inducible drug resistance risk is avoided under the condition without light. The application and the method are not limited by bacterial drug resistance, and provide solid and powerful technical support for treatment of the clinical multiple-drug-resistant acinetobacter baumannii.

The present invention provides compounds of formula (I)wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

The invention relates to the field of genetic engineering, and discloses PAL recombination protein of acinetobacter baumannii and a coding gene and application of the PAL recombination protein. The PAL recombination protein is (a) recombination protein as shown in SEQID NO:1 or SEQID NO:3; and (b) protein which is obtained by substituting, deleting and adding one or more amino acids for the aminoacid sequence as shown in SEQ ID NO:1 or SEQID NO:3, and has the same function as the recombination protein as shown in SEQID NO:1 or SEQID NO:3 and derived from (a) or protein which is prepared by connecting labels to the terminal of amino terminal and / or carboxyl terminal of the SEQID NO:1 or the SEQID NO:3 and shown in the amino acid sequence. The recombination protein is high in expression level, convenient to separate and purify, and high in efficacy and safe, can directly cooperate with an adjuvant for preparing a subunit vaccine and a relevant detection product, for resisting infectionof the acinetobacter baumannii.

The invention belongs to the technical field of microorganisms, and relates to marine-derived Aspergillus terreus M7 with an antibacterial effect, and separation and application of a secondary metabolite of the Aspergillus terreus M7. The strain is classified and named as Aspergillus terreus M7, and is preserved in China Center for Type Culture Collection (CCTCC) on June 7, 2021, with the preservation number of CCTCC NO: M 2021679. The strain is fermented by a soybean solid culture medium, and is subjected to methanol extraction, silica gel G chromatography, Sephadex LH-20 gel column chromatography, silica gel H chromatography and preparative liquid phase separation and purification to obtain a compound terramide A. The terramide A has obvious antibacterial activity on acinetobacter baumannii ATCC 19606, and has the potential of being developed into an antibacterial agent.

The invention relates to peptide nucleic acid probes used for rapidly detecting pseudomonas aeruginosa, klebsiella pneumoniae and / or baumanii through fluorescence in situ hybridization. The DNA sequences of the peptide nucleic acid probes are shown in SEQ NO: 1 and SEQ NO: 2. The invention further discloses a kit for identifying pseudomonas aeruginosa, klebsiella pneumoniae and / or baumanii and drug susceptibility of pseudomonas aeruginosa, klebsiella pneumoniae and / or baumanii in samples through the probe set, and use steps of the kit. The DNA extraction step is omitted, and the whole identification process generally consumes at most two hours; meanwhile, the false positive is low, a few steps are needed, efficiency is high, sensitiveness is high, and specificity is high. The pseudomonas aeruginosa, klebsiella pneumoniae and baumanii can be rapidly and accurately detected, and the peptide nucleic acid probes and the kit are of great importance in ensuring food safety, ensuring environmental health and preventing spreading of diseases.

The invention relates to an A1S-1462 recombinant protein and a preparation method and application thereof. The recombinant protein comprises A1S-1462 mature peptide, and the amino acid sequence of the recombinant protein is shown as SEQ ID NO. 3. The recombinant protein is high in expression amount, easy to separate and purify, efficient and safe, can be directly used with an adjuvant, and is used for the preparation of an acinetobacter baumannii infection resistant subunit vaccine and a related detection kit. Confirmed by animal experiments, the genetic engineering recombinant subunit vaccine has good acinetobacter baumannii infection resistant immune protection effect, lays a foundation for the further study on combined vaccines and multicomponent fusion vaccines, and plays an important role for development and application of prevention and control vaccines and diagnostic kits.

The invention discloses a transfer plasmid for transforming Acinetobacter baumannii, which comprises, in clockwise order, a replicon ori, an ampicillin resistance gene AmpR, a transposon sequence, a junction transfer initiation site oriT, the transposon sequence contains a base sequence capable of autonomously emitting Acinetobacter baumannii and a resistance gene, and both ends of the resistancegene are provided with DifR and DifL sequences; also disclosed is an autonomously illuminated Acinetobacter baumannii without a resistance marker, the gene of Acinetobacter baumannii containing a genecapable of expressing autonomous light-emitting protein, and no resistance screening gene is in the genome of Acinetobacter baumannii. In the present invention, the autonomously illuminated Acinetobacter baumannii, which is constructed by the transfer plasmid pUC18T-mini-Tn7T-lux-Ab-dif-Apr and the auxiliary plasmid pTNS3, can emit light without adding any substrate; and luminescent colonies canbe seen with the naked eye in a dark environment.

The invention relates to the technical field of medicines, in particular to application of a natural medicine in preparation of antibacterial medicines. According to the invention, various natural medicines can be used for preparing antibacterial medicines; mangiferin has a good inhibition effect on the growth of acinetobacter baumannii; the methyl caffeate has a good inhibition effect on acinetobacter baumannii; the invention also finds that harmine can be used as a synergist of meropenem to enhance the antibacterial effect of meropenem on klebsiella pneumoniae; single use of harmine or meropenem cannot inhibit the growth of klebsiella pneumonia, but when 128 [mu] g / mL harmine and 4 [mu] g / mL meropenem are combined for use, the growth of klebsiella pneumonia can be significantly inhibited, and the growth rate can be reduced to 5% or below.

The invention discloses an antibacterial peptide Scybaumancin105-127 and application thereof, the antibacterial peptide is found in Scylla paramamosain for the first time, the molecular formula of the antibacterial peptide is C106H188N36O28S3, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The antibacterial peptide Scybaumancin105-127 disclosed by the invention has good antibacterial activity on acinetobacter baumannii, shigella flexneri, escherichia coli, pseudomonas aeruginosa, cryptococcus neoformans, listeria monocytogenes, enterococcus faecium and propionibacterium acnes, and has no cytotoxicity on normal cells. The antibacterial peptide Scybaumancin105-127 has high antibacterial activity, safety and non-toxic, also has relatively strong antibacterial activity on clinical drug-resistant bacteria, and has a wide application prospect.

The invention discloses an antibacterial peptide HeHampI (67-92) and application thereof, which belong to the technical field of biology. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1. The antibacterial peptide HeHampI (67-92) has an obvious agglutination effect on gram-negative bacteria, gram-positive bacteria and fungi, is non-toxic to hippocampus embryonic cells, can remarkably inhibit release of free endotoxin of vibrio parahaemolyticus, acinetobacter baumannii and escherichia coli, can be used for preparing antibacterial preparations, and can be applied to aquaculture industry and medicine fields.